The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A Phase I/II trial.
 
Lajos Pusztai
Honoraria - BioTheranostics; celgene; Merck; Pfizer
Consulting or Advisory Role - Celgene; Clovis Oncology
Research Funding - Foundation Medicine; Genentech; Merck; Seagen
 
Andrea Silber
No Relationships to Disclose
 
Erin Wysong Hofstatter
No Relationships to Disclose
 
Gina G. Chung
No Relationships to Disclose
 
Nina Ruth Horowitz
No Relationships to Disclose
 
Donald R. Lannin
No Relationships to Disclose
 
Brigid K. Killelea
No Relationships to Disclose
 
Anees B. Chagpar
No Relationships to Disclose
 
Borbala Szekely
No Relationships to Disclose
 
Courtney Frederick
No Relationships to Disclose
 
Lawrence Rispoli
No Relationships to Disclose
 
Michael DiGiovanna
No Relationships to Disclose